Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Metaxalone
Drug ID BADD_D01400
Description Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression. Metaxalone is associated with few side effects and is available as a 800 mg scored tablet.
Indications and Usage For the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00660
KEGG ID D00773
MeSH ID C011301
PubChem ID 15459
TTD Drug ID D0S5CH
NDC Product Code 50228-323; 50228-474; 55700-911; 61919-832; 64980-472; 67296-1577; 68001-004; 68001-485; 68084-135; 69097-998; 0527-1435; 80425-0131; 12666-0012; 42494-449; 50268-530; 50436-0449; 53746-553; 67296-0993; 70518-0818; 75945-070; 0115-1745; 60687-663; 68040-712; 71205-961; 71335-0958; 63187-490; 63629-2398; 71205-326; 80425-0084; 65977-0089; 42291-587; 51655-602; 67296-1275; 70518-0771; 70934-429; 71205-016; 71335-1320; 17511-104; 50056-1999; 45865-985; 55700-494; 60760-289; 61919-091; 68788-7675; 69306-100; 45865-942; 51655-792; 0276-0508; 67296-1778; 68071-2849; 0904-6831; 60760-093; 63629-8014; 68788-7018; 69306-311; 0591-2341; 71335-2066; 0185-0448; 51655-171; 71205-426; 71205-470; 72789-028; 72789-122; 76420-232; 10920-581; 63629-2097; 65162-553; 68788-7499; 70518-2275; 70934-286; 80425-0122; 47621-020; 52076-6231; 73680-0011; 50090-3650; 55111-650
UNII 1NMA9J598Y
Synonyms metaxalone | Skelaxin | AHR 438
Chemical Information
Molecular Formula C12H15NO3
CAS Registry Number 1665-48-1
SMILES CC1=CC(=CC(=C1)OCC2CNC(=O)O2)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Asthenia08.01.01.0010.000780%Not Available
Ataxia17.02.02.001; 08.01.02.0040.000229%
Back pain15.03.04.0050.000780%
Cardiac arrest02.03.04.0010.000344%
Clonus17.02.05.0020.000229%Not Available
Coma17.02.09.0010.000803%Not Available
Completed suicide08.04.01.010; 19.12.01.0010.001262%Not Available
Delirium19.13.02.0010.000459%
Depressed level of consciousness17.02.04.0020.000803%
Dermatitis23.03.04.002--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug hypersensitivity10.01.01.0010.006239%Not Available
Drug ineffective08.06.01.0060.002340%Not Available
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.0280.000229%
Hyperreflexia17.02.01.0020.000459%Not Available
Hypersensitivity10.01.03.0030.000780%
Hypertension24.08.02.0010.000459%
Hypotension24.06.03.0020.001262%
Insomnia19.02.01.002; 17.15.03.0020.001170%
Irritability19.04.02.013; 08.01.03.011--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukopenia01.02.02.001--Not Available
Metabolic acidosis14.01.01.0030.000573%Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.000459%Not Available
Mydriasis17.02.11.003; 06.05.03.0040.000459%Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages